Universal STAR-T cell and preparation method thereof

Integrating and knocking out genes in STAR-T cells through the CRISPR/A.S.Cas12aUltra system solves the problems of cell reduction, carcinogenic risk and GVHD in CAR-T cell therapy, improves the durability and safety of the treatment, and provides more efficient Allogeneic universal STAR-T cell therapy regimen.

CN119060960APending Publication Date: 2024-12-03CHANGPING NAT LAB
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410695787.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing CAR-T cell therapies have cell reduction, technical errors, carcinogenic risks caused by lentiviruses, serious side effects, and treatment durability and safety problems. It is difficult to provide sufficient cellular therapy in a timely manner, and allotype CAR-T cells may cause GVHD. .

Method used

Through the CRISPR/A.S.Cas12aUltra system, STAR site-directed integration into endogenous TRAC, knock out the endogenous genes of specific T cells, optimize the phenotype of STAR-T cells, form allogeneic universal STAR-T cells, and improve their anti-tumor activity and safety and regulates STAR expression through endogenous TRAC genes to reduce GVHD risk.

Benefits of technology

Achieve better anti-tumor activity, safety and treatment durability of STAR-T cells, reduce treatment costs, and provide faster treatment options for a variety of patients, including those whose treatment is rapidly progressing or whose autologous cell therapy is not acceptable patient.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004869691290000051
    Figure BDA0004869691290000051
  • Figure BDA0004869691290000141
    Figure BDA0004869691290000141
  • Figure BDA0004869691290000151
    Figure BDA0004869691290000151
Patent Text Reader

Abstract

The invention relates to the field of immunotherapy, in particular to a preparation method of a general synthetic T-cell antigen receptor T cell (STAR-T), the STAR-T cell obtained by the preparation method and application of the STAR-T cell in treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of immunotherapy, and in particular, to a method for preparing universal synthetic T-cell antigen receptor T cells (STAR-T), the STAR-T cells obtained thereby, and their therapeutic uses. Background Art

[0002] In the past decade, CAR (Chimeric antigen receptor)-T cell therapy has made great achievements in the treatment of hematological tumors. After the FDA first approved Novartis' CD19 antigen-specific CAR-T cell KYMRIAH in 2017 for the treatment of relapsed or refractory acute lymphoblastic leukemia in patients aged 3-25 years and achieved great success, the research on CAR-T cell therapy has been expanded to the treatment of solid tumors.

[0003] Chimeric antigen receptor (CAR) is an artificially synthesized receptor that does not exist naturally. After continuous modification by scientists, the currently widely used structure consists of ScFv (single-chain variable fragment) that recognizes specific antigens at the extracellular end, a transmembrane hinge region, a CD3ζ intracellular activation domain, and two co-stimulatory signal molecules. Currently, CAR-T cell therapy is mostly autologous CAR-T cells, which are based on in vitro modification of patients' T cells. After collecting the patient's T cells, lentivirus is used to deliver the CAR that recognizes specific targets to the patient's T cells in a laboratory environment, and then the CAR is returned to the patient after expanded culture.

[0004] There are many potential risks in this process that prevent patients from obtaining enough CAR-T cells for reinfusion in time. For example, most patients have undergone chemotherapy or radiotherapy that can lead to a decrease in T cells before CAR-T cell therapy, making it difficult to obtain enough T cells for in vitro transformation and expansion culture. The patient's disease progresses too quickly, or there are technical errors in the production of CAR-T cells. These reasons may delay the treatment process and endanger the patient's life. Secondly, the vast majority of CAR-T cells are currently transformed using lentiviruses. Studies have shown that random insertion of lentiviruses into the T cell genome may cause rapid clonal proliferation, cell carcinogenic transformation, or transcriptional silencing, bringing unforeseen risks. Thirdly, CAR-T cell therapy also has serious side effects, the most typical of which is cytokine storm, which usually occurs within a week of reinfusion of CAR-T cells. The peak of CAR-T cell proliferation in the patient's body is very related to the severity of cytokine storm symptoms. Patients' symptoms include high fever, chills, headache, muscle pain, joint pain, and anorexia, and quickly progress to life-threatening tachycardia, hypotension, and hypoxia. Finally, after the T cells are infused back into the patient's body, they bind to tumor cell antigens, causing the T cells to be continuously activated and quickly exhausted, making the CAR-T cells less persistent in the patient's body and making the disease extremely likely to recur.

[0005] To solve the problem that patients cannot get cell therapy in time, allogeneic CAR-T cells meet the needs of some patients. Allogeneic CAR-T cells are modified by extracting T cells from healthy people's blood, but the antigen receptor TCR on the surface of allogeneic T cells may recognize surface antigens in the recipient's body, thereby triggering plant-versus-host disease (GVHD) that may be life-threatening.

[0006] Synthetic T-Cell Antigen Receptor T-Cell (STAR-T) has a highly efficient signaling capability similar to that of natural TCR complexes, and exhibits better anti-tumor activity than CAR-T targeting the same antigen, and has a lower level of self-activation and is less likely to cause adverse side effects. However, the durability and safety of STAR-T treatment still need to be further improved. Summary of the invention

[0007] After extensive research, the inventors of the present application, based on STAR-T, integrated STAR into endogenous TRAC based on the CRISPR / ASCas12aUltra system to obtain allogeneic universal STAR-T cells that can prevent GVHD, and further optimized the phenotype by knocking out one or more specific T cell endogenous genes. Compared with traditional STAR-T, STAR-T cells have better anti-tumor activity and safety, better self-renewal and in vivo amplification capabilities, and thus better therapeutic durability. In addition, since allogeneic preparation can be achieved, it can be stored in a "spot" form for timely use in treatment while greatly reducing costs, thereby bringing the possibility of treatment to more patients.

[0008] In an exemplary embodiment, in the universal STAR-T cells of the present application, the expression of the STAR is driven by the endogenous promoter of the endogenous TRAC gene of the T cells, thereby being able to effectively regulate the expression of exogenous STAR and improve the therapeutic durability and safety of STAR-T.

[0009] Engineered T cells

[0010] Therefore, in one aspect, the present application provides an engineered T cell expressing a synthetic T cell antigen receptor (STAR) that specifically binds to a tumor-associated antigen, wherein the engineered T cell comprises a first exogenous nucleic acid molecule inserted into an endogenous TRAC locus, the insertion resulting in silencing of expression of the endogenous TRAC gene, and the first exogenous nucleic acid molecule comprises a nucleotide sequence encoding STAR;

[0011] Furthermore, one or more T cell endogenous genes of the engineered T cells are knocked out;

[0012] Wherein, the STAR comprises a first peptide chain and a second peptide chain; the first peptide chain comprises a first antigen binding region and a first constant region, and the second peptide chain comprises a second antigen binding region and a second constant region;

[0013] wherein the first constant region is a T cell receptor α chain constant region, and the second constant region is a T cell receptor β chain constant region;

[0014] Wherein, the first antigen binding region and the second antigen binding region form an antigen binding site; the first antigen binding region comprises a heavy chain variable region of an antibody that specifically binds to the tumor-associated antigen, and the second antigen binding region comprises a light chain variable region of the antibody; or, the first antigen binding region comprises a light chain variable region of an antibody that specifically binds to the tumor-associated antigen, and the second antigen binding region comprises a heavy chain variable region of the antibody.

[0015] In certain embodiments, the first constant region is derived from a human T cell receptor alpha chain constant region.

[0016] In certain embodiments, the second constant region is derived from a human T cell receptor β chain constant region.

[0017] In certain embodiments, the first constant region is linked to the second constant region by a disulfide bond.

[0018] In certain embodiments, the knocked-out endogenous T cell gene is selected from endogenous genes involved in regulating the immune function state of T cells (eg, T cell differentiation, exhaustion or proliferation).

[0019] It is easy for those skilled in the art to understand that the endogenous genes involved in regulating the immune function status of T cells (such as T cell differentiation, exhaustion or proliferation) include, but are not limited to, genes of transcription factors related to T cell exhaustion and dysfunction, genes of T cell receptor TCR, genes of TCR signal inhibitors, genes of immunoinhibitory receptors, metabolism-related genes, genes of mitochondrial fission factors, genes of epigenetic regulatory factors, genes of cytokine receptors, genes of proinflammatory cytokines, genes of RNA binding proteins, GVHD-related genes, etc.

[0020] In certain embodiments, insertion of the first exogenous nucleic acid molecule is mediated by the CRISPR / ASCas12a Ultra system.

[0021] In certain embodiments, the engineered T cells comprise the effector protein AsCas12a Ultra and / or crRNA of the CRISPR / ASCas12a Ultra system.

[0022] In certain embodiments, the effector protein AsCas12a Ultra comprises an amino acid sequence as shown in SEQ ID NO: 39 or an ortholog, homolog, variant or functional fragment thereof.

[0023] In certain embodiments, the crRNA targets one or more endogenous genes of the engineered T cell.

[0024] In certain embodiments, the crRNA contains a scaffold sequence and a guide sequence, and the guide sequence is capable of specifically binding to a target sequence.

[0025] In certain embodiments, the scaffold sequence has a sequence as shown in SEQ ID NO: 40 or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 40.

[0026] In certain embodiments, the engineered T cell comprises one or more crRNAs. For example, the engineered T cell comprises a crRNA targeting one endogenous gene of the engineered T cell; or, the engineered T cell comprises multiple crRNAs respectively targeting multiple endogenous genes of the engineered T cell, or, the engineered T cell comprises multiple crRNAs that jointly target one endogenous gene of the engineered T cell.

[0027] In certain embodiments, when the crRNA targets the endogenous Regnase gene of a T cell, the guide sequence contained therein has a sequence as shown in any one of SEQ ID NOs: 3-14.

[0028] In certain embodiments, when the crRNA targets the endogenous BOCR gene of T cells, the guide sequence it comprises has a sequence as shown in any one of SEQ ID NOs: 15-30.

[0029] In certain embodiments, the first peptide chain and / or the second peptide chain each independently further comprises a co-stimulatory factor OX40.

[0030] In certain embodiments, the amino acid sequence of the co-stimulatory factor OX40 is as shown in SEQ ID NO:35.

[0031] In certain embodiments, the engineered T cells further comprise a second exogenous nucleic acid molecule inserted into the endogenous B2M (beta-2 microglobulin) locus, wherein the insertion results in silencing of expression of the endogenous B2M gene, and the second exogenous nucleic acid molecule comprises a nucleotide sequence encoding a fusion protein comprising an HLA-G signal peptide, B2M and HLA-E.

[0032] In certain embodiments, insertion of the second exogenous nucleic acid molecule is mediated by the CRISPR / ASCas12a Ultra system.

[0033] In certain embodiments, any two adjacent domains contained in the fusion protein are optionally connected by a peptide linker (eg, a peptide linker containing one or more glycine (G) and / or serine (S), eg, GGGGS).

[0034] In certain embodiments, the HLA-G signal peptide is located at the N-terminus of the fusion protein.

[0035] In certain embodiments, the fusion protein comprises, from N-terminus to C-terminus, the HLA-G signal peptide, the B2M and the HLA-E.

[0036] In certain embodiments, the HLA-G signal peptide has the amino acid sequence shown in SEQ ID NO:36, the B2M has the amino acid sequence shown in SEQ ID NO:37, and / or the HLA-E has the amino acid sequence shown in SEQ ID NO:38.

[0037] In certain embodiments, the knocked-out endogenous T cell gene is selected from the group consisting of: BCOR, REGNASE-1, TET2, and Roquin.

[0038] The T cell endogenous genes (e.g., BCOR, REGNASE-1, TET2, Roquin) involved in the present application have the meanings commonly understood by those skilled in the art. In certain embodiments, the relevant information of the T cell endogenous genes involved in the present application is shown in the following table:

[0039]

[0040] In certain embodiments, the endogenous BCOR gene, REGNASE-1 gene, or a combination thereof of the engineered T cells is knocked out.

[0041] In certain embodiments, the STAR is capable of forming a complex with a CD3 subunit endogenous to the engineered T cell (eg, one or more of the ε, δ, γ, ζ subunits).

[0042] In certain embodiments, the elements of the first peptide chain are optionally connected via a linker (e.g., a flexible peptide linker) or not, and / or the elements of the second peptide chain are optionally connected via a linker (e.g., a flexible peptide linker) or not.

[0043] In certain embodiments, the first constant region is a variant of a native T cell receptor α chain constant region comprising a cysteine ​​substitution relative to the native T cell receptor α chain constant region.

[0044] In certain embodiments, the amino acid sequence of the first constant region is shown in SEQ ID NO:31.

[0045] In certain embodiments, the second constant region is a variant of a native T cell receptor β chain constant region comprising a cysteine ​​substitution relative to the native T cell receptor β chain constant region.

[0046] In certain embodiments, the amino acid sequence of the second constant region is shown in SEQ ID NO:32.

[0047] In certain embodiments, the tumor-associated antigen is selected from the group consisting of: CD19, EGFR, CD20, CD16, CD64, CD78, CD96, CLL1, CD116, CD117, CD71, CD45, CD71, CD123, CD138, ErbB2 (HER2 / neu), carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), mesothelin MSLN, epidermal growth factor receptor (EGFR), EGFR variants III (EGFRvIII), CD19, CD20, CD30, CD40, disialoganglioside GD2, ductal epithelial mucin, gp36, TAG-72, glycosphingolipids, glioma-associated antigen, β-human chorionic gonadotropin, α-fetoprotein (AFP), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostase, prostate enzyme-specific antigen (PSA), PAP, NY-ESO-1, LAGA-1a, p53, Prostein, PSMA, survival and telomerase, prostate cancer tumor antigen-1 (PCTA-1), MAGE, ELF2M, neutrophil elastase, ephrin B2, CD22, insulin growth factor (IGF1)-I, IGF-II, IGF1 receptor, major histocompatibility complex (MHC) molecules presenting tumor-specific peptide epitopes, 5T4, ROR1, Nkp30, NKG2D, tumor stromal antigen, extra domain A (EDA) and extra domain B (EDB) of fibronectin, A1 domain of tenascin-C (TnC A1), fibroblast-associated protein (fap), CD3, CD4, CD8, CD24, CD25, CD33, CD34, CD133, CD138, Foxp3, B7-1 (CD80), B7-2 (CD86), GM-CSF, cytokine receptors, endoglin, major histocompatibility complex (MHC) molecules, BCMA (CD269, TNFRSF17), TNFRSF17 (UNIPROT Q02223), SLAMF7 (UNIPROT Q9NQ25), GPRC5D (UNIPROT Q9NZD1), FKBP11 (UNIPROT Q9NYL4), KAMP3, ITGA8 (UNIPROTP53708), and FCRL5 (UNIPROT Q68SN8).

[0048] In certain embodiments, the tumor-associated antigen is CD19.

[0049] In certain embodiments, the tumor-associated antigen is CD19, the amino acid sequence of the light chain variable region of the antibody that specifically binds to the antigen is shown in SEQ ID NO:34, and the amino acid sequence of the heavy chain variable region of the antibody that specifically binds to the antigen is shown in SEQ ID NO:33.

[0050] In certain embodiments, expression of the STAR is driven by the promoter of the endogenous TRAC gene in the T cell.

[0051] In certain embodiments, in the first exogenous nucleic acid molecule, the upstream of the STAR coding sequence does not contain an exogenous promoter.

[0052] In certain embodiments, in the first exogenous nucleic acid molecule, the coding sequence of the STAR contains a coding sequence of a self-cleaving polypeptide (eg, p2A) upstream.

[0053] In certain embodiments, the expression of the fusion protein is driven by an exogenous promoter (eg, an exogenous EF1α promoter).

[0054] In certain embodiments, in the second exogenous nucleic acid molecule, the exogenous promoter (eg, exogenous EF1α promoter) is contained upstream of the coding sequence of the fusion protein.

[0055] In certain embodiments, the insertion of the first exogenous nucleic acid molecule and / or the second exogenous nucleic acid molecule is mediated by the CRISPR / ASCas12a Ultra system.

[0056] Preparation method

[0057] In another aspect, the present application provides a method for preparing the engineered T cells as described above, comprising the following steps:

[0058] (1) inserting a first exogenous nucleic acid molecule into an endogenous TRAC locus of a T cell: (a) introducing a gene editing tool targeting an endogenous TRAC gene of a T cell into the T cell, thereby forming a double-strand break site in the endogenous TRAC gene; (b) introducing a first donor vector comprising the first exogenous nucleic acid molecule into the T cell, thereby homologously recombining the first exogenous nucleic acid molecule into the double-strand break site of the endogenous TRAC gene;

[0059] and,

[0060] (2) introducing a gene editing tool targeting one or more endogenous genes of the T cell into the T cell, thereby knocking out the one or more endogenous genes;

[0061] Wherein, steps (1) and (2) are performed in any order (for example, performed sequentially in any order, and / or, performed simultaneously);

[0062] Wherein, the gene editing tool is the CRISPR / ASCas12a Ultra system;

[0063] Wherein, the first exogenous nucleic acid molecule is as defined above, and the knocked-out endogenous gene is as defined above.

[0064] In certain embodiments, the first donor vector contains sequences homologous to the endogenous TRAC gene on both sides of the first exogenous nucleic acid molecule. In certain embodiments, the length of the homologous sequence is 300-500 bp.

[0065] In certain embodiments, in step (1), the first donor vector can be introduced into T cells simultaneously with or after the gene editing tool targeting the endogenous TRAC gene of T cells.

[0066] In certain embodiments, the method further comprises the step of inserting a second exogenous nucleic acid molecule into the endogenous B2M locus of the T cell, wherein the second exogenous nucleic acid molecule is as defined above, the step comprising:

[0067] (a) introducing a gene editing tool targeting an endogenous B2M gene of a T cell into the T cell, thereby forming a double-strand break site in the endogenous B2M gene; wherein the gene editing tool is a CRISPR / ASCas12a Ultra system;

[0068] (b) introducing a second donor vector comprising the second exogenous nucleic acid molecule into the T cell, thereby homologously recombining the second exogenous nucleic acid molecule into the double-strand break site of the endogenous B2M gene.

[0069] In some embodiments, the second donor vector contains sequences homologous to the endogenous B2M gene on both sides of the second exogenous nucleic acid molecule. In some embodiments, the length of the homologous sequence is 300-500 bp.

[0070] In certain embodiments, steps (1), (2) and the step of inserting a second exogenous nucleic acid molecule into the endogenous B2M locus of the T cell are performed in any order (e.g., sequentially in any order, and / or, one or more of them are performed simultaneously).

[0071] In certain embodiments, in the step of inserting the second exogenous nucleic acid molecule into the endogenous B2M locus of T cells, the second donor vector can be introduced into T cells simultaneously with or after the gene editing tool targeting the endogenous B2M gene of T cells.

[0072] In certain embodiments, the nucleotide sequence encoding the first peptide chain of STAR and the nucleotide sequence encoding the second peptide chain of STAR in the first exogenous nucleic acid molecule are connected by a coding sequence of a self-cleaving polypeptide (e.g., p2A) or a coding sequence of a protease (e.g., furin) recognition site.

[0073] In certain embodiments, the first donor vector and / or the second donor vector is AAV (adeno-associated virus).

[0074] In certain embodiments, in the first exogenous nucleic acid molecule, the upstream of the STAR coding sequence does not contain an exogenous promoter.

[0075] In certain embodiments, in the first exogenous nucleic acid molecule, the coding sequence of the STAR contains a coding sequence of a self-cleaving polypeptide (eg, p2A) upstream.

[0076] In certain embodiments, in the second exogenous nucleic acid molecule, the exogenous promoter (eg, exogenous EF1α promoter) is contained upstream of the coding sequence of the fusion protein.

[0077] In certain embodiments, in the CRISPR / ASCas12a Ultra system:

[0078] The guide sequence in the crRNA targeting the endogenous TRAC gene of T cells used has the sequence shown in SEQ ID NO: 1;

[0079] The guide sequence in the crRNA targeting the endogenous B2M gene of T cells used has the sequence shown in SEQ ID NO: 2;

[0080] The guide sequence in the crRNA targeting the endogenous Regnase gene of T cells used has a sequence as shown in any one of SEQ ID NOs: 3-14; and / or

[0081] The guide sequence in the crRNA targeting the endogenous BOCR gene of T cells used has a sequence as shown in any one of SEQ ID NOs: 15-30.

[0082] application

[0083] On the other hand, the present application provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a STAR and a nucleotide sequence encoding a fusion protein, wherein the fusion protein comprises an HLA-G signal peptide, B2M and HLA-E; wherein the STAR is as defined above; and the fusion protein is as defined above.

[0084] In certain embodiments, the nucleotide sequence encoding the first peptide chain of STAR and the nucleotide sequence encoding the second peptide chain of STAR are connected by a coding sequence of a self-cleaving polypeptide (eg, p2A) or a coding sequence of a protease (eg, furin) recognition site.

[0085] In certain embodiments, the nucleotide sequence encoding STAR contains sequences homologous to the endogenous TRAC gene of T cells on both sides. In certain embodiments, the homologous sequence is 300-500 bp in length.

[0086] In certain embodiments, the nucleotide sequence encoding B2M contains sequences homologous to the endogenous B2M gene of T cells on both sides. In certain embodiments, the homologous sequence is 300-500 bp in length.

[0087] In certain embodiments, the isolated nucleic acid molecule does not comprise an exogenous promoter between the downstream of the sequence homologous to the endogenous TRAC gene of the T cell and the upstream of the coding nucleotide sequence of the STAR at the 5' end; and the isolated nucleic acid molecule contains a coding sequence for a self-cleaving polypeptide (e.g., p2A) between the downstream of the sequence homologous to the endogenous TRAC gene of the T cell and the upstream of the coding nucleotide sequence of the STAR at the 5' end.

[0088] In certain embodiments, the isolated nucleic acid molecule further comprises an exogenous promoter (eg, an exogenous EF1α promoter) between the 5' end downstream of the sequence homologous to the endogenous B2M gene of the T cell and upstream of the nucleotide sequence encoding the fusion protein.

[0089] In certain embodiments, the isolated nucleic acid molecule further comprises a sequence of a crRNA (e.g., a crRNA derived from a CRISPR / ASCas12a Ultra system) targeting one or more endogenous genes of the engineered T cell or its coding sequence.

[0090] In certain embodiments, the isolated nucleic acid molecule comprises one or more crRNA sequences or their coding sequences. For example, the isolated nucleic acid molecule comprises a sequence of crRNA targeting one endogenous gene of the engineered T cell or its coding sequence; or, the isolated nucleic acid molecule comprises a plurality of crRNA sequences or their coding sequences that respectively target a plurality of endogenous genes of the engineered T cell, or, the isolated nucleic acid molecule comprises a plurality of crRNA sequences or their coding sequences that jointly target one endogenous gene of the engineered T cell.

[0091] In certain embodiments, the crRNA is as defined above.

[0092] In certain embodiments, the nucleotide sequence encoding STAR, the nucleotide sequence encoding the fusion protein, and the crRNA sequence or its coding sequence are each located in different nucleic acid molecules.

[0093] In another aspect, the present application provides a vector comprising the isolated nucleic acid molecule as described above.

[0094] In certain embodiments, the vector is an AAV vector.

[0095] In another aspect, the present application provides an immune cell composition comprising the engineered T cells as described above.

[0096] In certain embodiments, the number of engineered T cells accounts for at least 10% (e.g., 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%) of the total number of cells in the immune cell composition.

[0097] In another aspect, the present application provides the use of the engineered T cells, isolated nucleic acid molecules, vectors, or immune cell compositions described above for preparing a medicament for preventing and / or treating a tumor in a subject.

[0098] In certain embodiments, the STAR specifically binds an antigen expressed by the tumor.

[0099] In certain embodiments, the tumor expresses CD19.

[0100] In certain embodiments, the engineered T cells are derived from the subject.

[0101] In certain embodiments, the engineered T cells are derived from a donor other than the subject.

[0102] In certain embodiments, the tumor is selected from a solid tumor or a hematological tumor.

[0103] In certain embodiments, the tumor is selected from a malignancy of the B-cell lineage, such as a B-cell lymphoma or a B-cell leukemia, such as non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia.

[0104] In certain embodiments, the subject is a mammal, such as a human.

[0105] In another aspect, the present application provides a method for preventing and / or treating a tumor in a subject, the method comprising administering an effective amount of the engineered T cells, isolated nucleic acid molecules, vectors, or immune cell compositions described above to a subject in need thereof.

[0106] In certain embodiments, the method comprises administering to a subject in need thereof an effective amount of an immune cell composition as described above.

[0107] In certain embodiments, the STAR specifically binds an antigen expressed by the tumor.

[0108] In certain embodiments, the tumor expresses CD19.

[0109] In certain embodiments, the engineered T cells are derived from the subject.

[0110] In certain embodiments, the engineered T cells are derived from a donor other than the subject.

[0111] In certain embodiments, the tumor is selected from a solid tumor or a hematological tumor.

[0112] In certain embodiments, the tumor is selected from a malignancy of the B-cell lineage, such as a B-cell lymphoma or a B-cell leukemia, such as non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia.

[0113] In certain embodiments, the subject is a mammal, such as a human.

[0114] Definition of terms

[0115] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the virology, biochemistry, and immunology laboratory operation steps used herein are conventional steps widely used in the corresponding fields. At the same time, in order to better understand the present invention, the definitions and explanations of the relevant terms are provided below.

[0116] When the terms "for example," "such as," "including," "comprising," or variations thereof are used herein, these terms will not be considered as limiting terms, but will be interpreted to mean "but not limited to" or "not limited to."

[0117] The terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) should be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.

[0118] As used herein, the term "CRISPR / ASCas12a Ultra system" has the meaning commonly understood by those skilled in the art, and generally refers to a Class 2 CRISPR-Cas system derived from Acidaminococcus sp. In certain exemplary embodiments, the CRISPR / ASCas12a Ultra system comprises an effector protein AsCas12a Ultra and a guiding crRNA containing a scaffold sequence and a guide sequence, and the guide sequence specifically binds to a target sequence. In certain embodiments, the effector protein AsCas12a Ultra comprises an amino acid sequence as shown in SEQ ID NO: 39 or an ortholog thereof, a homolog, a variant or a functional fragment thereof, and the scaffold sequence has a sequence as shown in SEQ ID NO: 40 or a sequence having a substitution, deletion or addition of one or more amino acids (e.g., 1, 2, 3, 4 or 5 amino acids) compared to the sequence shown in SEQ ID NO: 40. In certain embodiments, the CRISPR / ASCas12a Ultra system or the effector protein contained therein can be purchased from IDT Corporation, Catalog Number: 10001273, and its product description is incorporated herein by reference.

[0119] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection so that the genetic material elements it carries are expressed in the host cell. Vectors are well known to those skilled in the art, and include but are not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or artificial chromosomes (PAC) derived from P1; bacteriophages such as lambda phage or M13 phage and animal viruses, etc. Animal viruses that can be used as vectors include but are not limited to retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex viruses), poxviruses, baculoviruses, papillomaviruses, papillomaviruses (such as SV40). A vector can contain a variety of elements that control expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selection elements and reporter genes. In addition, the vector may also contain a replication initiation site.

[0120] As used herein, the term "prevention" refers to a method implemented in order to prevent or delay the occurrence of a disease or illness or symptom (e.g., a tumor) in a subject. As used herein, the term "treatment" refers to a method implemented in order to obtain a beneficial or desired clinical result. For the purposes of the present invention, beneficial or desired clinical results include, but are not limited to, alleviating symptoms, reducing the scope of the disease, stabilizing (i.e., no longer worsening) the state of the disease, delaying or slowing the development of the disease, improving or alleviating the state of the disease, and alleviating symptoms (whether partially or completely), whether detectable or undetectable. In addition, "treatment" can also refer to, compared to the expected survival period (if not receiving treatment), extending the survival period.

[0121] As used herein, the term "subject" refers to a mammal, such as a primate mammal, such as a human. In certain embodiments, the subject (eg, human) has a tumor, or is at risk of having a tumor.

[0122] As used herein, the term "effective amount" refers to an amount sufficient to obtain or at least partially obtain the desired effect. For example, an effective amount for preventing a disease (e.g., a tumor) refers to an amount sufficient to prevent, stop, or delay the occurrence of a disease (e.g., a tumor); an effective amount for treating a disease refers to an amount sufficient to cure or at least partially stop the disease and its complications in a patient already suffering from the disease. Determining such an effective amount is well within the capabilities of those skilled in the art. For example, an effective amount for therapeutic use will depend on the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general condition such as age, weight and sex, the mode of administration of the drug, and other treatments administered simultaneously, etc.

[0123] The terms "cancer" and "tumor" are used interchangeably to refer to a broad class of diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division may lead to the formation of malignant tumors, or cells that invade neighboring tissues and may metastasize to distant parts of the body via the lymphatic system or bloodstream. Cancer includes both benign and malignant cancers as well as dormant tumors or micrometastases. Cancer also includes hematological malignancies.

[0124] The compilation of the twenty conventional amino acids involved in this article follows conventional usage. See, for example, Immunology-A Synthesis (2nd Edition, ES Golub and DR Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. In the present invention, the terms "polypeptide" and "protein" have the same meaning and are used interchangeably. And in the present invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.

[0125] Advantageous Effects of the Invention

[0126] The present application provides a method for preparing universal STAR-T cells based on the CRISPR / ASCas12aUltra system, which integrates STAR into endogenous TRAC to prevent GVHD, and further optimizes the phenotype by knocking out one or more specific T cell endogenous genes. The allogeneic universal STAR-T cells thus obtained have better anti-tumor activity and safety than traditional STAR-T, and have better self-renewal and in vivo amplification capabilities, thereby having better treatment persistence. Allogeneic universal STAR-T cells can bring the possibility of treatment to a large number of patients, including patients whose disease progresses very rapidly and cannot be treated in time, patients whose own T cells are severely damaged after multiple chemotherapy and radiotherapy and cannot undergo autologous cell therapy, and patients who cannot pay the huge cost of cell therapy, etc., and have huge application prospects and revolutionary.

[0127] Embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings and examples, but it will be appreciated by those skilled in the art that the following drawings and examples are only used to illustrate the present invention, rather than to limit the scope of the present invention. Various objects and advantages of the present invention will become apparent to those skilled in the art based on the following detailed description of the accompanying drawings and preferred embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0128] Figure 1 : Editing efficiency of individual crRNAs targeting genes BCOR and REGANASE-1.

[0129] Figure 2 :Schematic diagram of CRISPR knockin template.

[0130] Figure 3A :Flowchart of electroporation of human primary T cells.

[0131] Figure 3B: Efficiency of site-directed knock-in of FMC63-OX40STAR at the TRAC locus.

[0132] Figure 4 :In vitro killing function detection of universal STAR-T cells.

[0133] Figure 5 :In vivo functional verification of universal STAR-T cells in mice.

[0134] Sequence information

[0135] A description of the sequences involved in this application is provided in the table below.

[0136]

[0137] DETAILED DESCRIPTION

[0138] The invention will now be described with reference to the following examples which are intended to illustrate the invention rather than to limit the invention.

[0139] The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology, microbiology, cell biology, biochemistry and immunology, which are within the scope of those skilled in the art.

[0140] The embodiments of the present invention are described in detail below to provide a person of ordinary skill in the art with a full disclosure and description of how to conduct and utilize the test, screening and treatment methods of the present invention. It is understood by those skilled in the art that the embodiments describe the present invention by way of example and are not intended to limit the scope of the invention. For example, STAR targeting CD19 is only used as an example to explain the content of the present invention, and other known antibodies can replace the scFv part of STAR, which cannot be understood as a limitation of the present invention.

[0141] Example 1. Design of CrRNA targeting TRAC, B2M, REGNASE-1, and BCOR

[0142] Download the genome sequences of TRAC, B2M, REGNASE-1 and BCOR from PUBMED respectively, enter each sequence into the box of Step 1 on the page http: / / crispor.tefor.net / , select Homo sapiens-Human-UCSC Feb.2009(GRCh37 / hg19)+SNPs:1000Genomes,ExaC in Step 2, select TTT(A / C / G)-21bp-Cas12a(Cpf1)-21bp guides recommended by IDT in Step 3, and obtain a series of guide RNAs after Submit. Randomly select guide RNA sequences at different sites in the genome, and send the guide RNA sequence list to IDT for synthesis. The sequences are as follows (Table 1).

[0143] Table 1: crRNA used in Example 1

[0144]

[0145]

[0146] Example 2: Detecting CrRNA gene editing efficiency and selecting the optimal CrRNA for each gene

[0147] 1. Isolation and Culture of Primary Human T Cells

[0148] Obtain human peripheral blood cells, and purify CD4 and CD8 T cells using a complete T cell magnetic bead separation kit. Then, after stimulating and activating T cells in a culture dish coated with anti-CD3 / CD28 antibodies for 24-36 hours, wash the cells twice with RNase-free Opti-MEM, and resuspend them for the last time with the reagent in the LONZA P3 primary cell 4D nuclear transfection system X unit kit S, so that the final cell concentration is 1+E6 / 20μL.

[0149] 2. Preparation of RNP

[0150] Dissolve the ordered CrRNA in DEPC water to a final concentration of 75 μM. Order As.Cas12a Ultra protein from IDT at a concentration of 10 μg / μL. Mix 0.25 μL As.Cas12a Ultra and 0.5 μL of the ordered CrRNA, respectively, and incubate at 37°C for 15 min.

[0151] 3. Electroporation of RNP

[0152] Mix the incubated RNPs with 20 μL of cell suspension, gently pipette and transfer all of them into the electroporation cup in the LONZA P3 primary cell 4D nuclear transfection system X unit kit S, place it in the LONZA X unit electroporator, perform electroporation using the instrument's built-in EO115 program, and then transfer to the culture medium for culture.

[0153] 4. Extract Cell Genome

[0154] Four days after electroporation, 200 μL of cells (including cells that were not gene-edited as controls) were taken and the genome of the cells was extracted using the Tiangen Blood / Cell / Tissue Genomic DNA Extraction Kit.

[0155] 5. Design primers required to detect gene editing efficiency

[0156] The corresponding guide RNA sequences were found in the genome downloaded in Example 1, and PCR primers were designed about 300 bp upstream and downstream of the guide RNA sequences.

[0157] 6. Detecting gene editing efficiency

[0158] Use the genome extracted in step 4 above as a template, and perform PCR with the primers corresponding to the different guide RNAs in step 5 above. Each set of primers must have an unedited cell genome as a control. Sequence each PCR product to obtain files in ab1 and seq formats respectively. Open http: / / shinyapps.datacurators.nl / tide / , enter each guide RNA sequence in turn, upload the control group PCR ab1 format results and the experimental group PCR ab1 format results corresponding to the sequence, and after Update View, you can get the gene editing efficiency corresponding to each guide RNA. In this way, the optimal crRNA can be selected. The gene editing efficiency of each crRNA is as follows: Figure 1 As shown, the results showed that CrRNA3 of the BCOR gene can achieve the best editing efficiency, and CrRNA2 of the REGANASE-1 gene can achieve the best editing efficiency.

[0159] Example 3. Design of AAV vector for template required for CRISPR knockin

[0160] The template required for CRISPR knockin contains the following elements: Figure 2 ): 5' and 3' homology arms (5'HA and 3'HA), P2A sequence or exogenous promoter sequence, the gene to be inserted (GOI) and Poly A sequence.

[0161] In this example, the CD19-STAR structure was inserted into the TRAC site using the endogenous promoter of TRAC, and the HLA-G Signal peptide-B2M-HLAE trimer (hereinafter referred to as GBE) was inserted into the B2M gene using an exogenous promoter, and each monomer was connected with a G4S peptide linker. Therefore, a P2A spacer was used between the 5' homology arm of the TRAC site and the CD19 STAR, and an exogenous EF1α promoter was used between the 5' homology arm of the B2M site and the GBE.

[0162] The structure of the CD19-STAR is described as follows:

[0163] STAR targeting CD19 includes VH and VL of CD19-specific mouse monoclonal antibody (clone number FMC63), E1 TCRα chain constant region cysteine ​​mutant and E1 TCRβ chain constant region cysteine ​​mutant, and co-stimulatory factor OX40. The expressed STAR molecule STAR contains two polypeptide chains, including a first polypeptide chain formed by FMC63-VL, TCRβ chain and OX40, and a second polypeptide chain formed by FMC63-VH, TCRα chain and OX40. The gene sequences of the two polypeptide chains of STAR are connected by the coding sequences of furin and p2A protease cleavage sites. The gene sequences of the two polypeptide chains will be transcribed and translated into a fusion polypeptide together, and then cut into two independent protein subunits by the proteases corresponding to furin and p2A. The two subunits are covalently bound by disulfide bonds and form a complex with the endogenous CD3 subunits (ε, δ, γ, ζ) of T cells.

[0164] The amino acid sequence of the E1 TCR α chain constant region cysteine ​​mutant is SEQ ID NO: 31;

[0165] The amino acid sequence of the E1 TCRβ chain constant region cysteine ​​mutant is SEQ ID NO:32;

[0166] The amino acid sequence of the FMC63-VH is SEQ ID NO: 33;

[0167] The amino acid sequence of the FMC63-VL is SEQ ID NO: 34;

[0168] The amino acid sequence of OX40 is SEQ ID NO:35.

[0169] The structure of the HLA-G Signal peptide-B2M-HLAE trimer (GBE) is described as follows:

[0170] The GBE gene sequence includes the HLA-G signal peptide coding sequence, the full-length B2M gene sequence (excluding the start codon and the stop codon) and the full-length HLA-E gene sequence (excluding the start codon and the stop codon), and the three parts are connected by the coding sequence of the G4S peptide linker. Among them, the region targeted by the guideRNA in the B2M gene sequence in the GBE gene sequence is subjected to synonymous mutation to avoid the editing of the exogenous GBE gene by the imported B2M editing tool.

[0171] Example 4. AAV packaging

[0172] The template in Example 2 was cloned between the ITRs of the AAV vector, namely TRAC-P2A-CD19STAR and B2M-EF1α-GBE, and sent to Paigen Bio for AAV6 packaging.

[0173] Example 5, site-directed integration mediated by CRISPR / ASCas12aUltra system

[0174] According to steps 1-3 in Example 2, RNPs of TRAC, B2M, BCOR and REGNASE-1 were electroporated into PBMCs respectively (wherein, the guide sequence contained in the crRNA targeting TRAC is shown in SEQ ID NO: 1, the guide sequence contained in the crRNA targeting B2M is shown in SEQ ID NO: 2, the guide sequence contained in the crRNA targeting REGNASE-1 is shown in SEQ ID NO: 4, and the guide sequence contained in the crRNA targeting BCOR is shown in SEQ ID NO: 17). Within 30 minutes after electroporation, the corresponding TRAC-P2A-CD19STAR and B2M-EF1α-GBE were added to the cell culture medium at an MOI of 5E4, the culture medium was supplemented to a total volume of 200 μL and transferred to a 96-well plate, and transferred to a 48-well plate 2 days after electroporation, and passaged at 2e6 / ml according to the cell density. The gene knock-in efficiency was detected 4 days after electroporation ( Figure 3A ), and then expand the culture according to the cell density. For the TRAC site, this protocol uses the endogenous promoter of TRAC, uses the P2A sequence in the knockin template, and knocks in the FMC63-OX40STAR sequence at the site. The results are as follows Figure 3BAs shown, the knockout efficiency of TCR reached more than 99%, and the efficiency of FMC63-OX40STAR site-specific knock-in was 63.4%. Based on this, universal STAR-T cells have been obtained in this example. Subsequent experiments will simultaneously knock in FMC63-OX40STAR at the TRAC site, knock in EF1α-GBE at the B2M site, and knock out BCOR and REGNASE-1 at the same time, in order to obtain universal STAR-T cells that proliferate better in mice and have better tumor control.

[0175] Example 6: Functional verification of the obtained USTAR-T cells

[0176] The obtained USTAR-T cells (whose endogenous TRAC, B2M, BCOR and REGNASE-1 were knocked out, and FMC63-OX40STAR was site-introduced at the TRAC site, and EF1α-GBE was site-introduced at the B2M site) and Raji-Luc cells were co-cultured in a ratio of 2:1, 1:1, and 1:2, and target cell death and cytokine release were detected.

[0177] 1. Verification of T cell killing function: Luciferase detection

[0178] After co-culture of T cells and target cells for different time periods, the cell suspension was gently blown evenly, 150 μL of cell suspension was taken from each well and added to a white 96-well plate, centrifuged at 1500 rpm / min for 5 min, the supernatant was taken, and the cell lysis solution was added to lyse at room temperature for 15 min, and then centrifuged at 4°C, 4000 rpm / min for 15 min, the supernatant was taken, 2 duplicate wells were taken from each well, luciferase substrate (firefly luciferase detection reagent) was added, and the chemiluminescence value was detected using a multifunctional microplate reader, and the gain value was fixed at 100. Cell killing calculation: killing efficiency = 100% - (effect cell-target cell well value / control cell-target cell well value); wherein, "effect cell-target cell well value" refers to the luminescence value of the USTAR-T and target cell co-culture group, and "control cell-target cell well value" refers to the luminescence value of the blank T and target cell co-culture group.

[0179] The results are as follows Figure 4 As shown, CTL is a wild-type T cell, TCR KO is a T cell with TCR knocked out, TRAC-CD19STAR is a universal STAR-T cell, and the above T cells were co-cultured with Raji-luc expressing CD19. The results showed that the universal STAR-T cell had a good specific killing function against Raji-luc.

[0180] 2. Analysis of T cell secretion of cytokines: ELISA

[0181] During the activation of T cells, a large number of cytokines are released to help T cells kill target cells or promote the expansion of T cells themselves. Common cytokines include TNF-α, IFN-γ, and IL-2. After T cells are stimulated with target cells or antigens, they are collected, centrifuged, and the supernatant is taken. The TNF-α, IFN-γ, and IL-2 ELISA kits use Human IL-2 Uncoated ELISA, Human TNF-α Uncoated ELISA, and Human IFN-γ Uncoated ELISA (Cat. No. 88-7025, 88-7346, and 88-7316, respectively). The specific steps are: dilute 10X Coating Buffer to 1X with ddH2O, add coating antibody (250X), mix well, and add to a 96-well plate, 100μl / well. After sealing with plastic wrap, place at 4°C overnight, wash 3 times with 1X PBST (1X PBS with 0.05% Tween 20), 260μl / well each time, dilute 5XELISA / ELISPOT Diluent to 1X with ddH2O, add to 96-well plate, 200μl / well, and let stand at room temperature for 1h. Wash once with PBST, standard dilution (range: 2-250, 4-500, 4-500), and dilute the sample 20-50 times with 1xDiluent. Add samples and markers, 100 μL per well, duplicate wells, incubate at room temperature for 2 hours, wash three times with PBST, add detection antibody diluted with 1xDiluent, incubate for 1 hour, wash three times with PBST, then add HRP diluted with 1xDiluent, incubate for 30 minutes, wash six times, add TMB for color development, the color development time should not exceed 15 minutes, add 2N H2SO4 for termination, detect light absorption at 450nm, the results are as follows: Figure 4 shown.

[0182] Example 7: Functional verification of the obtained USTAR-T cells in mice

[0183] 1. Experimental Animal Model

[0184] This experiment uses NSG immunodeficient mice as a model. The mouse genotype is NOD-Prkdcem26Il2rgem26 / Nju, which lacks T cells, B cells, NK cells, and its macrophages and dendritic cells are also defective. NSG mice are currently the most complete immunodeficient mouse strain, and because they do not reject transplanted tumors and T cells, they are widely used in preclinical studies of T cell therapy. This experiment will use female NSG mice aged 6 to 8 weeks, and the weight difference of mice in each batch of experiments is controlled within 2g. Mice are housed in separate ventilated cages in a clean-grade barrier without specific pathogens (SPF), and are provided with normal diet and drinking water with a slightly acidic pH to prevent pathogen contamination.

[0185] 2. Animal Experiment Operation

[0186] All animal operations were performed after approval of the Animal Protocol.

[0187] 3. T cell safety assessment methods in animals

[0188] To evaluate the toxicity and safety of USTAR-T cells, it is possible to detect whether the cells cause side effects on experimental animals. By observing the behavioral state of mice, performing pathological analysis of mice, and analyzing the slices of important organs of mice, it is possible to evaluate whether the reinfused T cells have significant toxicity. At the same time, by performing T cell infiltration analysis on non-tumor tissues of mice, it is also possible to determine whether T cells have off-target killing effects on them. In addition, by detecting the levels of cytokines in the blood of mice, such as IL-2, IFN-γ, TNFα, or IL-6, it is possible to determine whether T cells will cause a systemic cytokine storm.

[0189] like Figure 5 A shows the experimental flow chart. First, 5×10 5 Raji-luc cells were injected into mice through the tail vein (Day-4). Four days later (Day0), the tumorigenic effect was detected and the mice were randomly divided into groups. On the second day (Day1), different groups of T cells (including BBzCAR-T cells as a control, where BBzCAR-T cells were prepared by infecting T cells from the same source as universal STAR-T cells with a lentivirus expressing anti-CD19 BBzCAR) were returned to each group of mice. Among them, the endogenous TRAC of the USTAR-T cells used was knocked out, and FMC63-OX40STAR was knocked into the TRAC site. The tumor growth of the mice was detected every 4 days thereafter ( Figure 5 B), Figure 5 C is the statistical result of tumor. After T cell transfusion, peripheral blood of mice was collected every week to detect the proliferation of T cells in the blood ( Figure 5D) The results showed that universal STAR-T cells had good tumor control function in mice and were superior to control CAR-T cells.

[0190] Although the specific embodiments of the present invention have been described in detail, those skilled in the art will understand that various modifications and changes can be made to the details without departing from the principles and purpose of the present invention according to all the teachings published, and these changes are within the scope of protection of the present invention. The entire invention is given by the attached claims and any equivalents thereof.

Claims

1. An engineered T cell expressing a synthetic T cell antigen receptor (STAR) that specifically binds to a tumor-associated antigen, wherein: The engineered T cell comprises a first exogenous nucleic acid molecule inserted into an endogenous TRAC gene locus, wherein the insertion results in silencing of expression of the endogenous TRAC gene, and the first exogenous nucleic acid molecule comprises a nucleotide sequence encoding STAR; Furthermore, one or more T cell endogenous genes of the engineered T cells are knocked out; Wherein, the STAR comprises a first peptide chain and a second peptide chain; the first peptide chain comprises a first antigen binding region and a first constant region, and the second peptide chain comprises a second antigen binding region and a second constant region; wherein the first constant region is a T cell receptor α chain constant region, and the second constant region is a T cell receptor β chain constant region; Wherein, the first antigen binding region and the second antigen binding region form an antigen binding site; the first antigen binding region comprises a heavy chain variable region of an antibody that specifically binds to the tumor-associated antigen, and the second antigen binding region comprises a light chain variable region of the antibody; or, the first antigen binding region comprises a light chain variable region of an antibody that specifically binds to the tumor-associated antigen, and the second antigen binding region comprises a heavy chain variable region of the antibody; Preferably, the first constant region is linked to the second constant region via a disulfide bond; Preferably, the knocked-out endogenous T cell gene is selected from endogenous genes involved in regulating the immune function state of T cells (eg, T cell differentiation, exhaustion or proliferation).

2. The engineered T cell of claim 1, wherein The insertion of the first exogenous nucleic acid molecule is mediated by the CRISPR / ASCas12aUltra system.

3. The engineered T cell of claim 1 or 2, wherein The engineered T cells contain the effector protein AsCas12a Ultra and / or crRNA of the CRISPR / ASCas12aUltra system; Preferably, the crRNA targets one or more endogenous genes of the engineered T cells.

4. The engineered T cell according to any one of claims 1 to 3, wherein The first peptide chain and / or the second peptide chain each independently further comprise a co-stimulatory factor OX40; Preferably, the amino acid sequence of the co-stimulatory factor OX40 is as shown in SEQ ID NO:

35.

5. The engineered T cell according to any one of claims 1 to 4, wherein The engineered T cell further comprises a second exogenous nucleic acid molecule inserted into the endogenous B2M (beta-2 microglobulin) locus, wherein the insertion results in silencing of the endogenous B2M gene expression, and the second exogenous nucleic acid molecule comprises a nucleotide sequence encoding a fusion protein, wherein the fusion protein comprises an HLA-G signal peptide, B2M and HLA-E; Preferably, the insertion of the second exogenous nucleic acid molecule is mediated by the CRISPR / ASCas12a Ultra system.

6. The engineered T cell of claim 5, wherein Any two adjacent domains contained in the fusion protein are optionally connected by a peptide linker (e.g., a peptide linker containing one or more glycine (G) and / or serine (S), e.g., GGGGS); Preferably, the HLA-G signal peptide is located at the N-terminus of the fusion protein; Preferably, the fusion protein comprises, from the N-terminus to the C-terminus, the HLA-G signal peptide, the B2M and the HLA-E; Preferably, the HLA-G signal peptide has the amino acid sequence shown in SEQ ID NO:36, the B2M has the amino acid sequence shown in SEQ ID NO:37, and / or the HLA-E has the amino acid sequence shown in SEQ ID NO:

38.

7. The engineered T cell according to any one of claims 1 to 6, wherein The knocked-out endogenous T cell gene is selected from: BCOR, REGNASE-1, TET2, and Roquin.

8. The engineered T cell according to any one of claims 1 to 7, wherein The endogenous BCOR gene, REGNASE-1 gene or a combination thereof of the engineered T cells is knocked out.

9. The engineered T cell according to any one of claims 1 to 8, wherein The STAR is capable of forming a complex with the endogenous CD3 subunits (eg, one or more of the ε, δ, γ, ζ subunits) of the engineered T cells.

10. The engineered T cell according to any one of claims 1 to 9, wherein The elements of the first peptide chain are optionally connected via a linker (e.g., a flexible peptide linker) or not, and / or the elements of the second peptide chain are optionally connected via a linker (e.g., a flexible peptide linker) or not.

11. The engineered T cell according to any one of claims 1 to 10, wherein The first constant region is a variant of a native T cell receptor α chain constant region comprising a cysteine ​​substitution relative to the native T cell receptor α chain constant region; Preferably, the amino acid sequence of the first constant region is as shown in SEQ ID NO:

31.

12. The engineered T cell according to any one of claims 1 to 11, wherein The second constant region is a variant of a native T cell receptor β chain constant region comprising a cysteine ​​substitution relative to the native T cell receptor β chain constant region; Preferably, the amino acid sequence of the second constant region is as shown in SEQ ID NO:

32.

13. The engineered T cell according to any one of claims 1 to 12, wherein The tumor-associated antigen is selected from the group consisting of: CD19, EGFR, CD20, CD16, CD64, CD78, CD96, CLL1, CD116, CD117, CD71, CD45, CD71, CD123, CD138, ErbB2 (HER2 / neu), carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), mesothelin MSLN, epidermal growth factor receptor (EGFR), EGFR variant III (EGFRvIII), CD19, CD20, CD30, CD40, disialoganglioside GD2, ductal epithelial mucin, gp36, TAG-72, glycosphingolipids, glioma-associated antigens, β-human chorionic gonadotropin, alpha fetoprotein (AFP), exogenous lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostase, prostate enzyme-specific antigen (PSA), PAP, NY-ESO-1, LAGA-1a, p53, Prostein, PSMA, survival and telomerase, prostate cancer tumor antigen-1 (PCTA-1), MAGE, ELF2M, neutrophil elastase, ephrin B2, CD22, insulin growth factor (IGF1)-I, IGF-II, IGF1 receptor, major histocompatibility complex (MHC) molecules presenting tumor-specific peptide epitopes, 5T4, ROR1, Nkp30, NKG2D, tumor stromal antigen, extra domain A (EDA) and extra domain B (EDB) of fibronectin, A1 domain of tenascin-C (TnC A1), fibroblast-associated protein (fap), CD3, CD4, CD8, CD24, CD25, CD33, CD34, CD133, CD138, Foxp3, B7-1 (CD80), B7-2 (CD86), GM-CSF, cytokine receptors, endoglin, major histocompatibility complex (MHC) molecules, BCMA (CD269, TNFRSF17), TNFRSF17 (UNIPROT Q02223), SLAMF7 (UNIPROT Q9NQ25), GPRC5D (UNIPROT Q9NZD1), FKBP11 (UNIPROT Q9NYL4), KAMP3, ITGA8 (UNIPROT P53708), and FCRL5 (UNIPROT Q68SN8); Preferably, the tumor-associated antigen is CD19; Preferably, the tumor-associated antigen is CD19, the amino acid sequence of the light chain variable region of the antibody that specifically binds to the antigen is shown in SEQ ID NO:34, and the amino acid sequence of the heavy chain variable region of the antibody that specifically binds to the antigen is shown in SEQ ID NO:

33.

14. The engineered T cell according to any one of claims 1 to 13, wherein The expression of STAR is driven by the promoter of the endogenous TRAC gene of the T cell; Preferably, in the first exogenous nucleic acid molecule, the upstream of the STAR coding sequence does not contain an exogenous promoter; Preferably, in the first exogenous nucleic acid molecule, the coding sequence of the STAR contains a coding sequence of a self-cleaving polypeptide (eg, p2A) upstream.

15. The engineered T cell according to any one of claims 1 to 14, wherein The expression of the fusion protein is driven by an exogenous promoter (e.g., an exogenous EF1α promoter); Preferably, in the second exogenous nucleic acid molecule, the exogenous promoter (eg, exogenous EF1α promoter) is contained upstream of the coding sequence of the fusion protein.

16. A method for preparing the engineered T cell of any one of claims 1 to 15, comprising the following steps: (1) inserting a first exogenous nucleic acid molecule into an endogenous TRAC locus of a T cell: (a) introducing a gene editing tool targeting an endogenous TRAC gene of a T cell into the T cell, thereby forming a double-strand break site in the endogenous TRAC gene; (b) introducing a first donor vector comprising the first exogenous nucleic acid molecule into the T cell, thereby homologously recombining the first exogenous nucleic acid molecule into the double-strand break site of the endogenous TRAC gene; and, (2) introducing a gene editing tool targeting one or more endogenous genes of the T cell into the T cell, thereby knocking out the one or more endogenous genes; Wherein, steps (1) and (2) are performed in any order (for example, performed sequentially in any order, and / or, performed simultaneously); Wherein, the gene editing tool is the CRISPR / ASCas12a Ultra system; Wherein, the first exogenous nucleic acid molecule is defined as in any one of claims 1 to 15, and the knocked-out endogenous gene is defined as in any one of claims 1 to 15; Preferably, the first donor vector contains sequences homologous to the endogenous TRAC gene on both sides of the first exogenous nucleic acid molecule; Preferably, in step (1), the first donor vector can be introduced into T cells simultaneously with or after the gene editing tool targeting the endogenous TRAC gene of T cells.

17. The method of claim 16, further comprising the step of inserting a second exogenous nucleic acid molecule into the endogenous B2M locus of the T cell, wherein the second exogenous nucleic acid molecule is defined as in any one of claims 1 to 15, the step comprising: (a) introducing a gene editing tool targeting an endogenous B2M gene of a T cell into the T cell, thereby forming a double-strand break site in the endogenous B2M gene; wherein the gene editing tool is a CRISPR / ASCas12a Ultra system; (b) introducing a second donor vector comprising the second exogenous nucleic acid molecule into the T cell, thereby homologously recombining the second exogenous nucleic acid molecule into the double-strand break site of the endogenous B2M gene; Preferably, the second donor vector contains sequences homologous to the endogenous B2M gene on both sides of the second exogenous nucleic acid molecule; Preferably, steps (1), (2) and the step of inserting the second exogenous nucleic acid molecule into the endogenous B2M locus of the T cell are performed in any order (e.g., performed sequentially in any order, and / or, one or more of them are performed simultaneously); Preferably, in the step of inserting the second exogenous nucleic acid molecule into the endogenous B2M locus of T cells, the second donor vector can be introduced into T cells simultaneously with or after the gene editing tool targeting the endogenous B2M gene of T cells.

18. The method of claim 16 or 17, wherein The nucleotide sequence encoding the first peptide chain of STAR and the nucleotide sequence encoding the second peptide chain of STAR in the first exogenous nucleic acid molecule are connected by the coding sequence of the self-cleaving polypeptide (eg, p2A) or the coding sequence of the protease (eg, furin) recognition site.

19. The method of any one of claims 16 to 18, wherein The first donor vector and / or the second donor vector is AAV (adeno-associated virus).

20. The method of any one of claims 16 to 19, wherein In the first exogenous nucleic acid molecule, the upstream of the STAR coding sequence does not contain an exogenous promoter; Preferably, in the first exogenous nucleic acid molecule, the coding sequence of the STAR contains a coding sequence of a self-cleaving polypeptide (eg, p2A) upstream.

21. The method of any one of claims 16 to 20, wherein In the second exogenous nucleic acid molecule, the exogenous promoter (eg, exogenous EF1α promoter) is contained upstream of the coding sequence of the fusion protein.

22. The method of any one of claims 16 to 21, wherein In the CRISPR / ASCas12aUltra system: The guide sequence in the crRNA targeting the endogenous TRAC gene of T cells used has the sequence shown in SEQ ID NO: 1; The guide sequence in the crRNA targeting the endogenous B2M gene of T cells used has the sequence shown in SEQ ID NO: 2; The guide sequence in the crRNA targeting the endogenous Regnase gene of T cells used has a sequence as shown in any one of SEQ ID NOs: 3-14; and / or The guide sequence in the crRNA targeting the endogenous BOCR gene of T cells used has a sequence as shown in any one of SEQ ID NOs: 15-30.

23. An isolated nucleic acid molecule comprising a nucleotide sequence encoding STAR and a nucleotide sequence encoding a fusion protein comprising an HLA-G signal peptide, B2M and HLA-E; wherein The STAR is defined in any one of claims 1 to 15; the fusion protein is defined in any one of claims 1 to 15; Preferably, the nucleotide sequence encoding the first peptide chain of STAR and the nucleotide sequence encoding the second peptide chain of STAR are connected via a coding sequence of a self-cleaving polypeptide (e.g., p2A) or a coding sequence of a protease (e.g., furin) recognition site; Preferably, the nucleotide sequence encoding STAR contains sequences homologous to the endogenous TRAC gene of T cells on both sides; Preferably, the nucleotide sequence encoding B2M contains sequences homologous to the endogenous B2M gene of T cells on both sides.

24. The isolated nucleic acid molecule of claim 23, wherein: (i) the isolated nucleic acid molecule does not contain an exogenous promoter between the downstream of the sequence homologous to the endogenous TRAC gene of the T cell and the upstream of the coding nucleotide sequence of the STAR at the 5' end; and the isolated nucleic acid molecule contains a coding sequence of a self-cleaving polypeptide (e.g., p2A) between the downstream of the sequence homologous to the endogenous TRAC gene of the T cell and the upstream of the coding nucleotide sequence of the STAR at the 5' end; and / or, (ii) the isolated nucleic acid molecule further comprises an exogenous promoter (eg, an exogenous EF1α promoter) between the downstream of the sequence homologous to the endogenous B2M gene of the T cell and the upstream of the nucleotide sequence encoding the fusion protein at the 5' end.

25. The isolated nucleic acid molecule of claim 23 or 24, further comprising a sequence of a crRNA (e.g., a crRNA derived from a CRISPR / ASCas12aUltra system) targeting one or more endogenous genes of the engineered T cell or a coding sequence thereof; Preferably, the guide sequence of the crRNA is as defined in claim 22.

26. A vector comprising the isolated nucleic acid molecule of any one of claims 23-25; Preferably, the vector is an AAV vector.

27. An immune cell composition comprising the engineered T cell of any one of claims 1-15.

28. Use of the engineered T cell of any one of claims 1 to 15, the isolated nucleic acid molecule of any one of claims 23 to 25, the vector of claim 26, or the immune cell composition of claim 27 for the preparation of a medicament for preventing and / or treating a tumor in a subject; Preferably, the STAR specifically binds to an antigen expressed by the tumor; Preferably, the tumor expresses CD19; Preferably, the engineered T cells are derived from the subject; Preferably, the engineered T cells are derived from a donor other than the subject; Preferably, the tumor is selected from a solid tumor or a blood tumor; Preferably, the subject is a mammal, such as a human.

Citation Information

Cited By

  • Antibody targeting BCMA and use thereof

    WO2026124586A1